Sigilon Therapeutics, Inc.   Report issue

For profit Phase 2
Founded: Cambridge MA United States (2015)
Status: Acquired by Eli Lilly (2023)

Organization Overview

First Clinical Trial
2020
NCT04541628
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Sigilon Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

sig-001 (1 trial)

sig-005 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hemophilia A (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2